Effect of Glycemic Control on Plasma Oxidized Low Density Lipoprotein Levels in Diabetics
Science Journal of Clinical Medicine
Volume 3, Issue 5, September 2014, Pages: 91-97
Received: Sep. 6, 2014; Accepted: Sep. 18, 2014; Published: Oct. 10, 2014
Views 2798      Downloads 128
Author
Koichi Ono, Department of Internal Medicine, Innoshima Medical Associated Hospital, Onomichi, Japan
Article Tools
Follow on us
Abstract
Objective: Increased low-density lipoprotein (LDL) glycation in diabetics could facilitate LDL oxidation, which is proatherogenic. I studied plasma oxidized LDL (OxLDL) levels in diabetics and non-diabetics, their relation to glycemic control, and their circadian variations. Methods: OxLDL in diabetics (n=32) and in non-diabetics without coronary artery diseases (n=20) were compared. OxLDL in diabetics (n=24) was measured on Days 2, 3, 4, 8 and the last day of hospitalization. Circadian variation in OxLDL in diabetics (n=18) was also examined. Glycemic control was implemented during hospitalization. Patients: The diabetics were divided into two groups; moderately-controlled (MC) group (HbA1c < 9.0% at admission, n = 15) and poorly-controlled (PC) group (HbA1c ≧ 9.0% at admission, n = 9). Results: In the MC group, OxLDL decreased by 20.8% after glycemic control (p = 0.0139), but not in the PC group. OxLDL is correlated with LDL on Days 3, 4, 8 (r = 0.837, 0.864, 0.801, respectively), TG on Day 8(r = 0.932), and Lp(a) at discharge (r = 0.871). In the PC group, OxLDL was 15.8% higher on the average in the daytime than at night (p = 0.0024). Conclusion: Plasma OxLDL is decreased by glycemic control, particularly in moderately glycemic controlled patients. OxLDL has a circadian variation, particularly in poorly glycemic controlled patients. Long-term glycemic control could reduce the progression of atherosclerosis, by reducing OxLDL levels.
Keywords
Diabetes Mellitus, Oxidized LDL, Circadian Variation
To cite this article
Koichi Ono, Effect of Glycemic Control on Plasma Oxidized Low Density Lipoprotein Levels in Diabetics, Science Journal of Clinical Medicine. Vol. 3, No. 5, 2014, pp. 91-97. doi: 10.11648/j.sjcm.20140305.13
References
[1]
“Epidemiology of Diabetes Interventions and Complications (EDIC) Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort,” Diabetes Care 22:99-111, 1999
[2]
K.T. Khaw, N. Wareham, R. Luben, S. Bingham, S. Oakes, et al., “Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk),” BMJ 322:15-18, 2001
[3]
A.I. Adler, H.A. Neil, S.E. Manley, R.R. Holman, and R.C. Turner, “Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom prospective diabetes study (UKPDS 47),” Am Heart J 138:S353-S359, 1999
[4]
E. Schleicher, T. Deufel, and O.H. Wieland,“Non-enzymatic glycosylation of human serum lipoproteins. Elevated epsilon-lysine glycosylated low density lipoprotein in diabetic patients,” FEBS Lett 129:1-4, 1981
[5]
E.C. Tsai, I.B. Hirsch, J.D. Brunzell, and A. Chait, “Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM,” Diabetes 43:1010-1014, 1996
[6]
K. Kobayashi, J. Watanabe, F. Umeda, and H. Nawata, “Glycation accelerates the oxidation of low density lipoprotein by copper ions,” Endocr J 42:461-465, 1995
[7]
A. Bowie, D. Owens, P. Collins, A. Johnson, and G.H. Tomkin, “Glycosylated low density lipoprotein is more sensitive to oxidation: implications for the diabetic patient?,” Atherosclerosis 102:63-67, 1993
[8]
G. Sobal, J. Menzel, and H. Sinzinger, “Why is glycated LDL more sensitive to oxidation than native LDL? A comparative study,” Prostaglandins Leukot Essent Fatty Acids. 63:177-86, 2000
[9]
S. Parthasarathy, N. Santanam, S. Ramachandran, and O. Meilhac, “Oxidants and antioxidants in atherogenesis: an appraisal,” J. Lipid Res. 40: 2143 – 2157, 1999
[10]
S. Parthasarathy, and S.M. Rankin, “Role of oxidized low density lipoprotein in atherogenesis,” Prog Lipid Res. 31:127-143, 1992
[11]
Y. Higashi, T. Peng, J. Du, S. Sukhanov, Y. Li, et al., “A redox-sensitive pathway mediates oxidized LDL-induced downregulation of insulin-like growth factor-1 receptor” J. Lipid Res. 46:1266-1277, 2005
[12]
S. Sukhanov, and P. Delafontaine, “Protein chip-based microarray profiling of oxidized low density lipoprotein-treated cells,” Proteomics 5:1274-1280, 2005
[13]
S. Sukhanov, Y.H. Song, and P. Delafontaine, “Global analysis of differentially expressed genes in oxidized LDL-treated human aortic smooth muscle cells,” Biochem. Biophys. Res. Commun. 306:443-449, 2003
[14]
Y. Li, Y. Higashi, H. Itabe, Y.H. Song, J. Du, et al., “Insulin-Like Growth Factor-1 Receptor Activation Inhibits Oxidized LDL-Induced Cytochrome C Release and Apoptosis via the Phosphatidylinositol 3 Kinase/Akt Signaling Pathway” Arterioscler Thromb Vasc Biol 23: 2178-2184, 2003
[15]
World Medical Association Declaration of Helsinki, “Recommendations guiding physicians in biomedical research involving human subjects,” Cardiovasc Res 35:2-3, 1997
[16]
S. Toshima, A. Hasegawa, M. Kurabayashi, H. Itabe, T. Takano, et al., “Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease,” Arterioscler Thromb Vasc Biol 20:2243-2247, 2000
[17]
H. Kohno, N. Sueshige, K. Oguri, H. Izumidate, T. Masunari, et al., “Simple and practical sandwich-type enzyme immunoassay for human oxidatively modified low density lipoprotein using antioxidized phosphatidylcholine monoclonal antibody and antihuman apolipoprotein-B antibody,” Clin Biochem 33:243-253, 2000
[18]
T. Shoji, Y. Nishizawa, M. Fukumoto, K. Shimamura, J. Kimura, et al., “Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels in healthy subjects,” Atherosclerosis 148:171-177, 2000
[19]
T.J. Lyons, R.L. Klein, J.W. Baynes, H.C. Stevenson, and M.F. Lopes-Virella, “Stimulation of cholesteryl ester synthesis in human monocyte-derived macrophages by low-density lipoproteins from type 1 (insulin-dependent) diabetic patients: the influence of non-enzymatic glycosylation of low-density lipoproteins,” Diabetologia 30:916-923, 1987
[20]
K. Katoh, “Possible relevance of lipid peroxidation and thromboxane production to the initiation and/or evolution of microangiopathy in non-hyperlipidemic type 2 diabetes mellitus,” Diabetes Res Clin Pract 18:89-98, 1992
[21]
W.A. Oranje, G.J. Rondas-Colbers, G.N. Swennen, H. Jansen, and B. Wolffenbuttel, “Lack of effect on LDL oxidation and antioxidant status after improvement of metabolic control in type 2 diabetes,” Diabetes Care 22:2083-2084, 1999
[22]
J.L. Sanchez-Quesada, R. Homs-Serradesanferm, J. Serrat-Serrat, J.R. Serra-Grima, F. Gonzalez-Sastre, et al., “Increase of LDL susceptibility to oxidation occurring after intense, long duration aerobic exercise,” Atherosclerosis 118:297-305, 1995
[23]
T.J. Vasankari, U.M. Kujala, T.M. Vasankari, and M. Ahotupa, “Reduced oxidized LDL levels after a 10-month exercise program,” Med Sci Sports Exerc 30:1496-1501, 1998
[24]
G. Sobal, J.E. Menzel, and H. Sinzinger, “Do E-series prostaglandins and their metabolites influence oxidation of native and glycated low-density lipoproteins?,” Prostaglandins Other Lipid Mediat 55:67-76, 1998
[25]
V. Gouaze, N. Dousset, J.C. Dousset, and P. Valdiguie, “Effect of nicotine and cotinine on the susceptibility to in vitro oxidation of LDL in healthy non smokers and smokers,” Clin Chim Acta 277:25-37, 1998
[26]
L. Cominacini, U. Garbin, A.M. Pastorino, A. Davoli, M. Campagnola, et al., “Predisposition to LDL oxidation in patients with and without angiographically established coronary artery disease,” Atherosclerosis 99:63-70, 1993
[27]
E. Maggi, E. Marchesi, V. Ravetta, A. Martignoni, G. Finardi, et al., “Presence of autoantibodies against oxidatively modified low-density lipoprotein in essential hypertension: a biochemical signature of an enhanced in vivo low-density lipoprotein oxidation,” J Hypertens 13:129-138, 1995
[28]
A. Hjalmarson, E.A. Gilpin, P. Nicod, H. Dittrich, H. Henning, et al. “Differing circadian patterns of symptom onset in subgroups of patients with acute myocardial infarction,” Circulation 80:267-275, 1989
[29]
J.R. Marler, T.R. Price, G.L. Clark, J.E. Muller, T. Robertson, et al., “Morning increase in onset of ischemic stroke,” Stroke 20:473-476, 1989
[30]
H. Yoshida, T. Ishikawa, and H. Nakamura, “Vitamin E/lipid peroxide ratio and susceptibility of LDL to oxidative modification in non-insulin-dependent diabetes mellitus,” Arterioscler Thromb Vasc Biol 17:1438-1446, 1997
[31]
S. Ehara, M. Ueda, T. Naruko, K. Haze, A. Itoh, et al., “Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes,” Circulation 103:1955-1960, 2001
[32]
K. Kugiyama, S. Sugiyama, H. Soejima, H. Kawano, T. Sakamoto, et al., “Increase in plasma levels of oxidized low-density lipoproteins in patients with coronary spastic angina,” Atherosclerosis 154:463-467, 2001
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186